Key result
Existing and emerging technologies for diagnosing endothelial cell dysfunction, including functional, structural, and surrogate markers, provide a foundation for future personalized screening.
This review summarizes existing and emerging technologies for diagnosing endothelial cell dysfunction to guide future personalized noninvasive screening.
Endothelial dysfunction diagnostics remain investigational; leaves open prospective validation before personalized screening adoption.
PURPOSE OF REVIEW: To briefly survey the literature for the past 2-3 years on the subject of diagnostic and prognostic markers of endothelial cell dysfunction. RECENT FINDINGS: Established and emerging techniques to detect endothelial cell dysfunction are divided into two large families: (1) functional and structural markers of endothelial cell dysfunction, and (2) surrogate markers of endothelial cell dysfunction. The first category includes high-resolution Doppler studies of conduit arteries, laser Doppler flowmetry of cutaneous microvasculature, and measurements of arterial stiffness and intima: media thickness. The second category of tests provides brief descriptions of detection of oxidative stress, inflammation, coagulation abnormalities, circulating endothelial cells and microparticles. I also focus on integration of various techniques and some novel genomic, proteomic and metabolomic tests. SUMMARY: This snapshot of existing and emerging technologies diagnosing endothelial cell dysfunction is intended to provide the foundation for the future (a) development of personalized noninvasive screening of endothelial function, and (b) delineation of preclinical diagnostic biomarkers heralding cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Michael S. Goligorsky (2006) conducted a review in Endothelial cell dysfunction. Diagnostic and prognostic markers of endothelial cell dysfunction was evaluated. Existing and emerging technologies for diagnosing endothelial cell dysfunction, including functional, structural, and surrogate markers, provide a foundation for future personalized screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: